Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an announcement.
Prescient Therapeutics Limited has announced a live and interactive shareholder briefing to discuss their Share Purchase Plan, which will be led by CEO James McDonnell. The company is advancing its clinical development programs, with PTX-100 showing promising results in treating T cell lymphomas, and their innovative cell therapy platforms, CellPryme and OmniCAR, enhancing the effectiveness of adoptive cell therapies. These developments position Prescient as a significant player in the personalized oncology treatment market, potentially benefiting stakeholders through improved cancer treatments.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine approaches to cancer treatment, including targeted and cellular therapies. Their primary products include PTX-100, a unique GGT-1 inhibitor for cancer treatment, and various cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR, which enhance the effectiveness of cell therapies and enable multi-antigen targeting.
Average Trading Volume: 932,117
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$33.02M
Learn more about PTX stock on TipRanks’ Stock Analysis page.